GAURAV TRIKHA, MD

Nuclear medicine study from skull base to mid-thigh with ct scan

Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Ct scan of abdomen and pelvis with contrast

Ct scan of chest with contrast

Biopsy of bone marrow

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Injection, zoledronic acid, 1 mg

New patient office or other outpatient visit, 45-59 minutes

Established patient office or other outpatient visit, 40-54 minutes

Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

New patient office or other outpatient visit, 30-44 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Established patient office or other outpatient visit, 30-39 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Infusion into a vein for hydration, 31-60 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Injection, pembrolizumab, 1 mg

Established patient office or other outpatient visit, 20-29 minutes

Infusion, normal saline solution , 1000 cc

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Administration of chemotherapy into vein, each additional hour

Injection, palonosetron hcl, 25 mcg

Established patient office or other outpatient visit, 10-19 minutes

Telephone medical discussion with physician, 5-10 minutes

Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services

Injection, carboplatin, 50 mg

Injection of additional new drug or substance into vein

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Injection of drug or substance under skin or into muscle

Injection, denosumab, 1 mg

Injection, granisetron hydrochloride, 100 mcg

Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count

Infusion into a vein for hydration, each additional hour

Blood creatinine level

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units

Injection, gadoterate meglumine, 0.1 ml

Injection, leucovorin calcium, per 50 mg

Insertion of needle into vein for collection of blood sample

Urinalysis, manual test

Injection, fluorouracil, 500 mg

Injection, fosaprepitant, 1 mg

Injection, oxaliplatin, 0.5 mg

Injection, diphenhydramine hcl, up to 50 mg

Injection, ferric carboxymaltose, 1 mg